Skip to main content

Table 1 Effect of prednisolone, interleukin (IL)-4 or IL-4/prednisolone treatment on the joint pathology of collagen-induced arthritis in Mice

From: Protection against cartilage and bone destruction by systemic interleukin-4 treatment in established murine type II collagen-induced arthritis

    Cartilage Proteoglycan Bone  
Treatment Dose Infiltrate destruction loss erosin n
Vehicle - 2.3 ± 0.9 2.2 ± 0.9 2.7 ± 1.0 1.9 ± 0.9 20
Prednisolone 0.05 2.1 ± 0.8 2.1 ± 1.2 2.6 ± 0.6 1.7 ± 1.1 20
IL-4 0.1 2.5 ± 0.7 2.5 ± 0.8 2.9 ± 0.3 2.0 ± 0.8 10
IL-4 1 2.0 ± 1.0 1.2 ± 0.8* 2.0 ± 0.7 0.6 ± 0.6* 20
IL-4/prednisolone 0.1/0.05 2.1 ± 0.4 1.6 ± 0.7 2.5 ± 0.8 2.1 ± 0.6 10
IL-4/prednisolone 1/0.05 1.2 ± 0.5* 1.1 ± 0.9* 1.4 ± 0.7* 0.4 ± 0.5* 10
  1. Histopathology scores of arthritic knee joints after treatmentwith vehicle, IL-4, prednisolone or the combination of IL-4/prednisolone. Micewere sacrified and knee joints were used for histology. Histology was scored asindicated in the Materials and methods section. Mice were treated twice a dayintraperitoneally with either prednisolone (0.05 mg/kg), or IL-4 (0.1 or 1μg/day], or IL-4 (at both dosages) combined with prednisolone(0.05 mg/kg). *P <0.05, versus vehicle, by Mann-Whitney Utest.